Gyre Therapeutics/$GYRE
1D1W1MYTD1Y5YMAX
Capital at risk
About Gyre Therapeutics
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
- Ticker
- $GYRE
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 625
- Headquarters
- San Diego, United States
- Website
- www.gyretx.com
GYRE Metrics
BasicAdvanced
$709M
-
-$0.21
4.81
-
Price and volume
Market cap
$709M
Beta
4.81
52-week high
$9.42
52-week low
$5.44
Average daily volume
64K
Financial strength
Current ratio
4.259
Quick ratio
3.587
Long term debt to equity
0.012
Total debt to equity
0.021
Profitability
EBITDA (TTM)
-12.131
Gross margin (TTM)
93.80%
Net profit margin (TTM)
-19.33%
Operating margin (TTM)
-13.90%
Effective tax rate (TTM)
-15.15%
Revenue per employee (TTM)
$180,000
Management effectiveness
Return on assets (TTM)
-5.42%
Return on equity (TTM)
-17.44%
Valuation
Price to revenue (TTM)
5.708
Price to book
6.57
Price to tangible book (TTM)
6.86
Price to free cash flow (TTM)
-87.695
Free cash flow yield (TTM)
-1.14%
Free cash flow per share (TTM)
-0.076
Growth
Revenue change (TTM)
-3.38%
Earnings per share change (TTM)
1,479.83%
3-year revenue growth (CAGR)
-1.07%
3-year earnings per share growth (CAGR)
74.52%
Bulls say / Bears say
Company reaffirmed full-year 2026 revenue guidance of $100.5 million to $111.0 million following Q2 results, signaling management’s confidence in its commercial and pipeline outlook (SEC)
NMPA’s acceptance of the NDA for F351 (hydronidone) in May 2026 provides regulatory validation for its lead fibrosis therapy and opens the door to CHB-induced liver fibrosis treatment in China (Reuters)
Six-month revenue rose to $53.5 million from $45.8 million a year earlier, driven by a 19% increase in ETUARY sales, demonstrating strong commercial execution (EveryTicker)
Q2 2026 revenue declined 2% year-over-year to $29.1 million, weighed down by a $9.6 million drop in collaboration revenue under the Astellas agreement and pricing headwinds from China’s national procurement program on Etorel and Contiva (Market Inference
bulls: []
createTime
Data summarised monthly by Lightyear AI. Last updated on 29 Aug 2026.
Upcoming events
No upcoming events
Funds containing GYRE
Fund name | Fund size | $GYRE weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.